Cytokinetics Incorporated (CYTK)
CYTK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/0001193125-26-076495-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CYTK on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2004 |
| SEC CIK | 0001061983 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $88.0M |
| Net income | -$785.0M |
| Operating income | -$612.3M |
| Net margin | -891.6% |
| Operating margin | -695.4% |
| Revenue growth | +376.6% |
| Cash | $122.5M |
| Total assets | $1.4B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 84.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $203.4M cash; operating cash flow -$143.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 139,303,351 (2026-11-02); 122,264,929 a year earlier; 98,053,647 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-05-07 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Jose, California, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $52.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $47.6M | -$190.1M | -$124.0M | $203.4M | $418.7M | $113.3M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $28.6M | -$198.8M | -$159.8M | $255.3M | $275.6M | $67.7M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $19.4M | -$206.0M | -$145.5M | $129.8M | $292.0M | $105.8M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $17.8M | -$183.0M | -$142.7M | $122.5M | $287.6M | $88.0M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $1.9M | -$306.2M | -$107.5M | $225.5M | $1.0B | $87.2M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $66.8M | -$134.4M | -$128.2M | $74.9M | $609.7M | $85.7M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $1.6M | -$161.4M | -$131.6M | $73.7M | $610.1M | $19.2M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $16.9M | -$150.0M | -$65.6M | $94.9M | $619.5M | $18.5M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-07 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEF 14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.5% |
| 1 month | -8.9% |
| 3 months | -23.6% |
| Year to date | -11.7% |
| 1 year | -14.3% |
| From 52-week high | -35.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International plc | $94.23 | -2.18% | $7.4B |
| AMRX | Amneal Pharmaceuticals Inc. | $21.23 | -0.70% | $7.4B |
| RYTM | Rhythm Pharmaceuticals Inc. | $107.48 | -6.56% | $7.5B |
| ABVX | Abivax SA | $83.61 | -4.53% | $7.3B |
| CORT | Corcept Therapeutics Incorporated | $69.22 | -5.10% | $7.6B |
| AXSM | Axsome Therapeutics Inc. | $137.01 | -3.30% | $7.2B |
| ALKS | Alkermes plc | $46.53 | -1.06% | $7.8B |
| PTGX | Protagonist Therapeutics Inc. | $124.83 | -4.67% | $8.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier